Catalyst Pharmaceuticals (CPRX) Cash Flow Statement

Click line-items for a historical chart and %

Operating Activities:
Net loss	-13.91M
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	31.44K
Stock-based compensation	1.35M
Change in assets and liabilities:
Decrease in government grant receivable
Decrease (increase) in prepaid expenses and deposits	1.19M
Increase in accounts payable	-738.8K
Increase (decrease) in accrued expenses and other liabilities	-697.4K
Net cash used in operating activities
Investing Activities:
Capital expenditures	-88.93K
Purchase of certificate of deposit
Net cash used in investing activities
Financing Activities:
Proceeds from issuance of common stock, net
Proceeds from issuance of preferred stock, net
Payment of employee withholding tax related to RSUs	-11.27K
Net cash provided by financing activities
Net (decrease) increase in cash	-10.6M
Cash and cash equivalents at beginning of period	28.24M
Cash and cash equivalents at end of period	17.64M
Supplemental disclosure of non-cash operating activity:
Non-cash incentive received from lessor	0

Entities mentioned with CPRX